Atypical tauopathy in a patient with LRRK2-G2019S mutation and tremor-dominant Parkinsonism

Neuropathology and Applied Neurobiology

Volumn 38, Issue 4, 2012, Pages 382-386

  Ruffmann, C ^a   Giaccone, G ^b   Canesi, M ^a   Bramerio, M ^c   Goldwurm, S ^a   Gambacorta, M ^c   Rossi, G ^b   Tagliavini, F ^b   Pezzoli, G ^a  

^a PARKINSON INSTITUTE   (Italy)

^b DEPARTMENT OF NEUROSURGERY   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

G2019S PROTEIN; IOFLUPANE I 123; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; PERGOLIDE; PROTEIN; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADL DISABILITY; AGED; BRADYKINESIA; CASE REPORT; COGNITIVE DEFECT; DEPRESSION; DRUG DOSE INCREASE; DYSKINESIA; GENE MUTATION; GLIOSIS; HAPLOTYPE; HOMOZYGOSITY; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; LEWY BODY; LIMB TREMOR; MALE; MINI MENTAL STATE EXAMINATION; NEUROFIBRILLARY TANGLE; PARKINSONISM; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBSTANTIA NIGRA; TAUOPATHY; UNIFIED PARKINSON DISEASE RATING SCALE;

AGED; HUMANS; MALE; MUTATION; PARKINSONIAN DISORDERS; PROTEIN-SERINE-THREONINE KINASES; TAUOPATHIES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREMOR;

EID: 84860901516     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/j.1365-2990.2011.01216.x     Document Type: Letter

References (17)

1. Rajput A, Dickson DW, Robinson CA, Ross OA, Dachsel JC, Lincoln SJ, Cobb SA, Rajput ML, Farrer MJ. Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology 2006; 67: 1506-8.
2. Wszolek ZK, Pfeiffer RF, Tsuboi Y, Uitti RJ, McComb RD, Stoessl AJ, Strongosky AJ, Zimprich A, Muller-Myhsok B, Farrer MJ, Gasser T, Calne DB, Dickson DW. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 2004; 62: 1619-22.
3. Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 2003; 18: 738-50.
4. Goldwurm S, Zini M, Di Fonzo A, De Gaspari D, Siri C, Simons EJ, van Doeselaar M, Tesei S, Antonini A, Canesi M, Zecchinelli A, Mariani C, Meucci N, Sacilotto G, Cilia R, Isaias IU, Bonetti A, Sironi F, Ricca S, Oostra BA, Bonifati V, Pezzoli G. LRRK2 G2019S mutation and Parkinson's disease: a clinical, neuropsychological and neuropsychiatric study in a large Italian sample. Parkinsonism Relat Disord 2006; 12: 410-19.
5. Baker M, Litvan I, Houlden H, Adamson J, Dickson D, Perez-Tur J, Hardy J, Lynch T, Bigio E, Hutton M. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet 1999; 8: 711-15.
6. Alafuzoff I, Arzberger T, Al-Sarraj S, Bodi I, Bogdanovic N, Braak H, Bugani O, Del-Tredici K, Ferrer I, Gelpi E, Giaccone G, Graeber MB, Ince P, Kamphorst W, King A, Korkolopoulou P, Kovacs GG, Larionov S, Meyronet D, Monoranu C, Parchi P, Patsouris E, Roggendorf W, Seilhean D, Tagliavini F, Stadelmann C, Streichenberger N, Thal DR, Wharton SB, Kretzschmar H. Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BraiNet Europe Consortium. Brain Pathol 2008; 18: 484-6.
7. Williams DR, de Silva R, Paviour DC, Pittman A, Watt HC, Kilford L, Holton JL, Revesz T, Lees AJ. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain 2005; 128: 1247-58.
8. Wider C, Dickson DW, Wszolek ZK. Leucine-Rich Repeat Kinase 2 gene-associated disease: redefining genotype-phenotype correlation. Neurodegener Dis 2010; 7: 175-9.
9. Hernandez D, Paisan Ruiz C, Crawley A, Malkani R, Werner J, Gwinn-Hardy K, Dickson D, Wavrant DeVrieze F, Hardy J, Singleton A. The dardarin G2019S mutation is a common cause of Parkinson's disease but not other neurodegenerative diseases. Neurosci Lett 2005; 389: 137-9.
10. Madzar D, Schulte C, Gasser T. Screening for LRRK2 R1441 mutations in a cohort of PSP patients from Germany. Eur J Neurol 2009; 16: 1230-2.
11. Gaig C, Ezquerra M, Marti MJ, Valldeoriola F, Munoz E, Llado A, Rey MJ, Cardozo A, Molinuevo JL, Tolosa E. Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration. J Neurol Sci 2008; 270: 94-8.
12. Ross OA, Whittle AJ, Cobb SA, Hulihan MM, Lincoln SJ, Toft M, Farrer MJ, Dickson DW. LRRK2 R1441 substitution and progressive supranuclear palsy. Neuropathol Appl Neurobiol 2006; 32: 23-5.
13. Williams DR, Holton JL, Strand C, Pittman A, De Silva R, Lees AJ, Revesz T. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. Brain 2007; 130: 1566-76.
14. Spanaki C, Latsoudis H, Plaitakis A. LRRK2 mutations on Crete: R1441H associated with PD evolving to PSP. Neurology 2006; 67: 1518-19.
15. Greggio E, Cookson MR. Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro 2009; 1: 13-24.
16. Santpere G, Ferrer I. LRRK2 and neurodegeneration. Acta Neuropathol 2009; 117: 227-46.
17. Tobin JE, Latourelle JC, Lew MF, Klein C, Suchowersky O, Shill HA, Golbe LI, Mark MH, Growdon JH, Wooten GF, Racette BA, Perlmutter JS, Watts R, Guttman M, Baker KB, Goldwurm S, Pezzoli G, Singer C, Saint-Hilaire MH, Hendricks AE, Williamson S, Nagle MW, Wilk JB, Massood T, Laramie JM, DeStefano AL, Litvan I, Nicholson G, Corbett A, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Sherman S, Al-Hinti J, Drasby E, Nance M, Moller AT, Ostergaard K, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH. Haplotypes and gene expression implicate the MAPT region for Parkinson disease. Neurology 2008; 71: 28-34.